AIRLINK 62.48 Increased By ▲ 2.05 (3.39%)
BOP 5.36 Increased By ▲ 0.01 (0.19%)
CNERGY 4.58 Decreased By ▼ -0.02 (-0.43%)
DFML 15.50 Increased By ▲ 0.66 (4.45%)
DGKC 66.40 Increased By ▲ 1.60 (2.47%)
FCCL 17.59 Increased By ▲ 0.73 (4.33%)
FFBL 27.70 Increased By ▲ 2.95 (11.92%)
FFL 9.27 Increased By ▲ 0.21 (2.32%)
GGL 10.06 Increased By ▲ 0.10 (1%)
HBL 105.70 Increased By ▲ 1.49 (1.43%)
HUBC 122.30 Increased By ▲ 4.78 (4.07%)
HUMNL 6.60 Increased By ▲ 0.06 (0.92%)
KEL 4.50 Decreased By ▼ -0.05 (-1.1%)
KOSM 4.48 Decreased By ▼ -0.09 (-1.97%)
MLCF 36.20 Increased By ▲ 0.79 (2.23%)
OGDC 122.92 Increased By ▲ 0.53 (0.43%)
PAEL 23.00 Increased By ▲ 1.09 (4.97%)
PIAA 29.34 Increased By ▲ 2.05 (7.51%)
PIBTL 5.80 Decreased By ▼ -0.14 (-2.36%)
PPL 107.50 Increased By ▲ 0.13 (0.12%)
PRL 27.25 Increased By ▲ 0.74 (2.79%)
PTC 18.07 Increased By ▲ 1.97 (12.24%)
SEARL 53.00 Decreased By ▼ -0.63 (-1.17%)
SNGP 63.21 Increased By ▲ 2.01 (3.28%)
SSGC 10.80 Increased By ▲ 0.05 (0.47%)
TELE 9.20 Increased By ▲ 0.71 (8.36%)
TPLP 11.44 Increased By ▲ 0.86 (8.13%)
TRG 70.86 Increased By ▲ 0.95 (1.36%)
UNITY 23.62 Increased By ▲ 0.11 (0.47%)
WTL 1.28 No Change ▼ 0.00 (0%)
BR100 6,944 Increased By 65.8 (0.96%)
BR30 22,827 Increased By 258.6 (1.15%)
KSE100 67,142 Increased By 594.3 (0.89%)
KSE30 22,090 Increased By 175.1 (0.8%)

WHO approves China’s Sinopharm vaccine for emergency use

  • WHO gave emergency use listing to Beijing's Sinopharm Covid-19 vaccine, making it the sixth overall, and the first Chinese vaccine to receive WHO validation for safety, efficacy, and quality.
Published May 7, 2021

The World Health Organization (WHO) on Friday approved the Sinpoharm vaccine for emergency use against the Covid-19. With this development, Sinopharm became China’s first coronavirus vaccine to get the WHO’s nod for international use.

Addressing a press conference in this regard, the WHO’s director-general, Tedros Adhanom Ghebreyesus said:

“This afternoon, WHO gave emergency use listing to Beijing's Sinopharm Covid-19 vaccine, making it the sixth vaccine to receive WHO validation for safety, efficacy, and quality.”

The other five emergency use vaccines to get WHO listings are made by Pfizer-BioNTech, Moderna, Johnson, and Johnson, and the AstraZeneca being produced at separate sites in India and in South Korea.

The approval means that Sinopharm will be included in Covax, the UN health agency’s global initiative that is designed to promote equitable vaccine distribution around the world.

According to an AFP, the Sinopharm vaccine being used in 42 territories around the world, is the fourth behind AstraZeneca (166), Pfizer-BioNTech (94), and Moderna (46).

Besides China, it is being used in Algeria, Cameroon, Egypt, Hungary, Iraq, Iran, Pakistan, Peru, the United Arab Emirates, Serbia, and Seychelles, among others.

It is a developing story, will be updated accordingly.

Comments

Comments are closed.